		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="1">
		</amp-ad>
				</div>
			</div>
		</div><p>Johnson &; Johnson has asked US regulators to clear the world’s first single-dose coronavirus vaccine, an easier-to-use option that could boost scarce supplies.</p>
<p>Preliminary results from a massive study of 44,000 people in the US, Latin America and South Africa showed the jab was safe and offered strong protection against moderate to severe Covid-19.</p>
<p>It did not appear quite as strong as two-dose competitors made by Pfizer and Moderna.</p>
<blockquote class="twitter-tweet" data-width="550" data-dnt="true">
<p lang="en" dir="ltr">Johnson &; Johnson announced that <a href="https://twitter.com/JanssenGlobal?ref_src=twsrc%5Etfw">@JanssenGlobal</a> has submitted an application to the <a href="https://twitter.com/US_FDA?ref_src=twsrc%5Etfw">@US_FDA</a> requesting Emergency Use Authorization of its investigational single-dose <a href="https://twitter.com/hashtag/COVID19?src=hash&;ref_src=twsrc%5Etfw">#COVID19</a> vaccine candidate. Read more: <a href="https://t.co/Yx4P5Rk16P">https://t.co/Yx4P5Rk16P</a> <a href="https://t.co/e9P0NaiGAB">pic.twitter.com/e9P0NaiGAB</a></p>
<p>&mdash; Johnson &; Johnson (@JNJNews) <a href="https://twitter.com/JNJNews/status/1357469710321922048?ref_src=twsrc%5Etfw">February 4, 2021</a></p></blockquote>
<p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p>
<p>Overall, the single-dose vaccine was 66% effective at preventing moderate to severe Covid-19 but it was 85% protective against the most serious symptoms — and starting 28 days after their shot, researchers found no one who got the vaccine needed hospitalisation or died.</p>
<p>Johnson &; Johnson filed an application with the Food and Drug Administration (FDA) on Thursday.</p>
<p>An FDA panel will meet later this month and pore over the results.</p>
<p>Dr Peter Marks, FDA’s vaccine chief, has cautioned against making comparisons before the evidence is all in.</p>
<p>“With so much need to get this pandemic under control, I think we can’t ignore any tool in the tool chest,” he told the American Medical Association last week.</p>
<p>“We will have to do our best to try to make sure that we find the populations that benefit the most from each of these vaccines and deploy them in a very thoughtful manner.”</p>
<p>J&;J also is studying a two-dose version of its vaccine, but results will not be available for several more months.</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-68ed5032c176b">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-68ed5032c176b',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
